Navigation Links
Mylan Launches Generic Version of Risperdal® M-Tab®
Date:5/13/2011

PITTSBURGH, May 13, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Risperidone Orally Disintegrating Tablets (ODT), 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the generic version of Ortho-McNeil's Risperdal® M-Tab®, a treatment for schizophrenia.  

Risperidone ODT had U.S. sales of approximately $61 million for the 12 months ending Dec. 31, 2010, according to IMS Health.

Currently, Mylan has 169 ANDAs pending FDA approval representing $100.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Launches First Generic Version of Femara® Tablets
2. Mylan Launches Generic Version of Famvir® Tablets
3. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
4. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
5. Moodys Upgrades Mylan
6. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®
7. Mylan Receives Approval for Generic Version of Neurontin® Capsules
8. Mylan Launches First Generic Version of Vfend® Tablets
9. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
10. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
11. Mylan Announces Lipitor® Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 9.2% over the next decade to reach approximately $8.9 ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... 2017  Spheryx, Inc. will present two ... PittCon 2017 Conference and Exposition at McCormick ... largest annual premier conference and exposition on ... of industry, academic and government communities encompassing ... safety, environmental, bioterrorism and other emerging markets.  ...
(Date:2/23/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ( ... and dermatology biopharmaceutical company, today announced that it has ... as special advisers to the Company,s Board of ... board on financial and corporate strategy. Provectus ... of up to $2.5 million from Eric Wachter ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & ... in the fight against cancer, has produced a seminal study that asked cancer ... release top-line findings in a webinar, Defining Compassionate Care Through the Voices of ...
Breaking Medicine News(10 mins):